drugset / Trial / NCT02093910

Efficacy of Monosialotetrahexosylganglioside in the Prophylactic Treatment of Bortezomib-induced Peripheral Neuropathy

NCT02093910 ↗

Phase 2 Unknown 100 enrolled Sun Yat-sen University
Non-randomizedSingle-groupOpen-labelSupportive care

Summary

Bortezomib was an important drug in the treatment of multiple myeloma (MM),and peripheral neuropathy (PN) is a significant dose-limiting toxicity of bortezomib that typically occurs within the first courses of bortezomib, reaches a plateau at cycle 5. Up to now, no effective prophylaxis have been developed for PN. Monosialotetrahexosylganglioside, a nerve-protecting drug,was often used to promote growth of nerve, and function restoration of damaged nerve.Thus,the investigators hypothesized that combination of Monosialotetrahexosylganglioside and bortezomib can reduce the incidence rate of peripheral neuropathy (PN) and promote the relief of peripheral neuropathy (PN) in multiple myeloma (MM) patients.

Timeline

Start
2014-04
Primary completion
2017-04
Completion
2018-04

Drugs

EvaluationDrugModalityDoseRoute
Subject monosialotetrahexosylganglioside Sodium Unknown 100 mg Intravenous

Indications